INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigat...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 3, 2023

Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y • Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research • Statement from Minister Hutchings on progress in support of rural Canadians • Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin • The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve • Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting • San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat • 56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award • Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting • Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl • High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy • UNice Celebrates LGBTQ Pride Month • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo • Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam • KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line • Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf • Bijou Ikli named new CEO by Florida Assisted Living Association

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Integra Digital Turbine, Inc. and Encou

LOS ANGELES , May 26 /Businesswire/ - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Digital Turbine, Inc. (“Digital Turbine” or “the Company”) (NASDAQ: APPS) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.